Congress 107 - HR 1530 - Prescription Drug Competition Act of 2001

Sponsor

Cosponsors

Topics

Administrative procedure Antitrust law Civil actions and liability Commerce Drug approvals Drug industry Federal Trade Commission Fines (Penalties) Generic drugs Government Operations and Politics Government paperwork Health Independent regulatory commissions Injunctions Law Marketing Pharmaceutical research Research and development Restrictive trade practices Science, Technology, Communications

Full Text

View Full Bill Text

Votes

Summary

Prescription Drug Competition Act of 2001 - Requires brand name drug companies and generic drug applicants to file with the Federal Trade Commission and the Secretary of Health and Human Services specified information regarding any agreement regarding the sale or manufacture of a generic drug which the Secretary has determined is the therapeutic equivalent of the brand name drug or for which the applicant seeks a determination of therapeutic equivalence, if such agreement could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.

Actions

Oct 11, 2001

Sponsor introductory remarks on measure. (CR S10642-10643)
Apr 25, 2001

Referred to the Subcommittee on Health.
Apr 4, 2001

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2001

Introduced in House

Amendments

Related Bills